Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Pre Market
Current status date:
2023-03-10
Original market date: See footnote 1
Product name:
ROPIVACAINE HYDROCHLORIDE INJECTION, USP
DIN:
02439395
Product Monograph/Veterinary Labelling:
Date:
2019-10-07
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
FRESENIUS KABI CANADA LTD
165 Galaxy Blvd, Suite 100
Toronto
Ontario
Canada
M9W 0C8
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Nerve Block , Epidural
Number of active ingredient(s):
1
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
72:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
N01BB09 ROPIVACAINE
Active ingredient group (AIG) number:See footnote5
0133273004
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| ROPIVACAINE HYDROCHLORIDE | 7.5 MG / ML |